Athena Athena

X
[{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sumitomo Dainippon Pharma and Exscientia Joint Development New Drug Candidate Created Using Artificial Intelligence (AI) Begins Clinical Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"JAPAN","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sumitomo Dainippon, Exscientia begin study of AI based OCD drug","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"JAPAN","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Poxel","pharmaFlowCategory":"D","amount":"$21.3 million","upfrontCash":"Undisclosed","newsHeadline":"Poxel Announces Submission of Imeglimin Japanese New Drug Application for the Treatment of Type 2 Diabetes by Sumitomo Dainippon Pharma","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Myovant Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Myovant Sciences Announces Further Financing Support from Sumitomo Dainippon Pharma and Commercial Collaboration with Sunovion Pharmaceuticals","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sumitomo Dainippon Pharma Oncology to Present New Data Evaluating Investigational Agent Alvocidib at 62nd ASH Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Exscientia","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exscientia Announces Second Molecule Created Using AI From Sumitomo Dainippon Pharma Collaboration to Enter Phase 1 Clinical Trial","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sumitomo Dainippon Pharma Oncology Provides Update on Phase 3 WIZARD 201G Study of Ombipepimut-S Emulsion (DSP-7888) in Patients with Recurrent or Progressive Glioblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Sumitovant Biopharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sumitomo Dainippon Pharma and Sumitovant Biopharma Initiate Phase 1 Study on New Drug Candidate for Carbapenem-Resistant Bacterial Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Veneno Technologies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Veneno Technologies, a Novel DRP Drug Discovery Company, Announces Joint Research Agreement with Sumitomo Pharma Co. Ltd.","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Technology","graph2":"Discovery"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Poxel","pharmaFlowCategory":"D","amount":"$299.0 million","upfrontCash":"$42.0 million","newsHeadline":"Poxel and Sumitomo Dainippon Pharma Announce the Approval of TWYMEEG\u00ae (Imeglimin hydrochloride) for the Treatment of Type 2 Diabetes in Japan","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"JCR Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"JCR and Sumitomo Dainippon Pharma Enter into Marketing Alliance for Agalsidase Beta BS I.V. Infusion, for Treatment of Fabry Disease in Japan","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Cell and Gene therapy","productStatus":"Biosimilar","date":"March 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sumitomo Pharma Announces Authorization in Canada of ORGOVYX\u00ae (relugolix) for the Treatment of Men with Advanced Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"October 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Sumitomo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sumitomo Pharma Announces Authorization in Canada of Orgovyx for Treatment Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"October 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals by Sumitomo Dainippon Pharma Co., Ltd

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            ORGOVYX (relugolix), is the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist, for the treatment of men with advanced prostate cancer.

            Lead Product(s): Relugolix

            Therapeutic Area: Oncology Product Name: Orgovyx

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 24, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Orogvyx (relugolix), is the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist, for the treatment of men with advanced prostate cancer.

            Lead Product(s): Relugolix

            Therapeutic Area: Oncology Product Name: Orgovyx

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 23, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the agreement, Veneno will conduct a program to obtain functional peptides (DRPs) for ion channels targeted by Sumitomo Pharma using Veneno Technologies' next-generation peptide discovery technology, the PERISS™ method (intra-periplasm secretion and selection).

            Lead Product(s): Undisclosed

            Therapeutic Area: Technology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Peptide

            Recipient: Veneno Technologies

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement April 18, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The agreement includes the marketing alliance for JR-051 (agalsidase beta BS), a biosimilar of Fabrazyme, a therapeutic enzyme, being sold by JCR for the treatment of Fabry disease.

            Lead Product(s): Agalsidase Beta

            Therapeutic Area: Genetic Disease Product Name: JR-051

            Highest Development Status: Approved Product Type: Cell and Gene therapy

            Recipient: JCR Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement March 01, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            It appears from nonclinical data that KSP-1007 broadly and strongly inhibits β-lactamases, which are enzymes that are produced by bacteria that can degrade carbapenem antibiotics. Sumitovant is leading the program of the compound in the U.S.

            Lead Product(s): KSP-1007,Meropenem

            Therapeutic Area: Infections and Infectious Diseases Product Name: KSP-1007

            Highest Development Status: Phase I Product Type: Small molecule

            Recipient: Sumitovant Biopharma

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 10, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            This study evaluated the safety and efficacy of DSP-7888, an investigational WT1 immunotherapeutic cancer vaccine, in combination with bevacizumab versus bevacizumab alone in patients with recurrent or progressive GBM following initial therapy.

            Lead Product(s): Ombipepimut,Bevacizumab

            Therapeutic Area: Oncology Product Name: DSP-7888

            Highest Development Status: Phase III Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 15, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The companies entered into a strategic partnership for the development and commercialization of Twymeeg (imeglimin hydrochloride) in Japan, China, South Korea, Taiwan and nine other Southeast Asian countries.

            Lead Product(s): Imeglimin Hydrochloride

            Therapeutic Area: Endocrinology Product Name: Twymeeg

            Highest Development Status: Approved Product Type: Small molecule

            Recipient: Poxel

            Deal Size: $299.0 million Upfront Cash: $42.0 million

            Deal Type: Partnership June 23, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Clinical study of DSP-0038, a dual targeted 5-HT1A agonist and 5-HT2A antagonist to be assessed for treatment of Alzheimer’s disease psychosis.

            Lead Product(s): DSP-0038

            Therapeutic Area: Neurology Product Name: DSP-0038

            Highest Development Status: Phase I Product Type: Small molecule

            Recipient: Exscientia

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 13, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Zella 201 is a biomarker-driven study of alvocidib followed by cytarabine and mitoxantrone in patients with relapsed/refractory MCL-1 dependent acute myeloid leukemia. Data presented will include findings from an exploratory cohort of newly diagnosed, high-risk patients.

            Lead Product(s): Alvocidib,Mitoxantrone,Cytarabine

            Therapeutic Area: Oncology Product Name: Flavopiridol

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 06, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Myovant has entered into a three-year commercial collaboration agreement with Sunovion Pharmaceuticals for services to support the planned commercialization of investigational drug candidate relugolix.

            Lead Product(s): Relugolix

            Therapeutic Area: Oncology Product Name: MVT-601

            Highest Development Status: Phase III Product Type: Small molecule

            Recipient: Myovant Sciences

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration August 05, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY